4Hayer-Eatinn B,RT.Update in the epidemiology,prophylaxis and treatment of fungal infection in patient with hematologic disorders[J].Leukemia Lymphoma,2004,45:669-680.
5Sander MA,Ronald AR.Update in infections diseases[J].Am J Intern Med,2004,140:290-295.
7Grear ND.Voriconazole:the newest triazole antifungal agent[J].Baylor Univ Med Center Proceed,2003,16:241-248.
8Pfallerr MA,Diekema DJ,Masser SA,et al.In vitro activities of voriconazole,pasoconazole and four licensed systemic antifungal agents against candida species infrequently isolated form blood[J].J Clin Microb,2003,41:78-83.
9Boogaerts MA,Maertens J,Van Der Geest R,et al.Pharmacokinetics and safety of a 7-days adminstration of intravenous itraconazole followed by a 14-days adminstration of itraconazole oral solution in patients with hematologic malignancy[J].Antimicrob Agents Chemother,2001,45:981-985.
10Johnson HB,Kaeffmen CA.Voriconazole:A new triazole antifungal agent[J].Clin Infect Dis,2003,36:610-617.
4Fisk DT, Meshniek S, Kazanjian PH. Pneumocystis carinii pneumo- nia in patients in the developing world who have acquired immuno- deficiency syndrome[J]. Clin Infect Dis, 2003, 36:70-78.
5Catherinot E, Lanternier F, Bougnoux ME, etal. Pneumocystis jir- ovecii pneumonia[J]. Infect Dis Clin North Am, 2010, 24:107-138.
6Armstrong-James D, Stebbing J, John L, et al. A trial of caspofungin salvage treatment in PCP pneumonia[J]. Thorax, 2011, 66:537-538.
7Wang XL, Wei W, An CL. Retrospective study of Pneumocystis pneumonia over half a century in China's Mainland[J]. J Med Microbi- ol, 2011, 60:631-638.
8Yasuoka A, Tachikawa N, Shimada K, et al. (1-->3) beta-D-glu-can as a quantitative serological marker for Pneumocystis carinii pneumonia[J]. Clin Diagn Lab Immunol, 1996, 3:197-199.
9Shimizu A, Oka H, Matsuda T, et al. (1-->3)- beta- D glucan is a diagnostic and negative prognostic marker for Pneumocystis carinii pneumonia in patients with connective tissue disease[J]. Clin Exp Rheumatol, 2005, 23:678-680.
10Utili R, Durante-Mangoni E, Basilico C, et al. Efficacy of caspofun- gin addition to trimethoprim-sulfamethoxazole treatment for severe pneumocystis pneumonia in solid organ transplant recipients[J]. Transplantation, 2007, 84:685-688.
